Pozen Migraine Agent Advisory Cmte. Postponed; August Meeting Possible

Tardive dyskinesia risk with MT-100, the metoclopromide/naproxen combination product for migraine, continues to be the focus of a committee meeting, Pozen says. NDA filing for sumatriptan/naproxen migraine product Trexima is planned for the third quarter.